A recent study out of the United Kingdom finds patients with relapsed malignant mesothelioma can be treated effectively with single-agent nivolumab, safely improving overall and…
Using accelerated high-dose radiation prior to surgery produced an unprecedented 65.9-month median survival for a cohort of pleural mesothelioma patients who were part of a…
The ONCOS-102 immunotherapy vaccine continues its move toward future, first-line standard of care treatment for malignant pleural mesothelioma, based upon the latest study follow-up…
A much-anticipated, phase III clinical trial studying the use of gene therapy to combat pleural mesothelioma cancer has made a promising start. Interest…
Pharmaceutical giant Merck has teamed up with Novocure to test its cornerstone immunotherapy, pembrolizumab (Keytruda), alongside Tumor Treating Fields. The new phase II…
Standard-of-care treatment for unresectable pleural mesothelioma cancer could be changing soon, sparked by a recently completed international study of a novel immunotherapy combination.
Your web browser is no longer supported by Microsoft. Update your browser for more security, speed and compatibility.
If you are looking for mesothelioma support, please contact our Patient Advocates at (855) 404-4592
Who Am I Calling?
Calling this number connects you with a Patient Advocate at The Mesothelioma Center, the nation's most trusted mesothelioma resource.
Our Patient Advocates can help guide you or your loved one through the steps to take after a mesothelioma diagnosis. Our team has a combined experience of more than 30 years in assisting cancer patients, and includes a medical doctor, an oncology registered nurse and a U.S. Navy veteran.
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Please read our editorial guidelines to learn more about our content creation and review process.
